Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial

American Heart Journal

Volumn 166, Issue 5, 2013, Pages

  Latini, Roberto ^a   Staszewsky, Lidia ^a   Sun, Jie Lena ^b   Bethel, M Angelyn ^b,c   Disertori, Marcello ^d   Haffner, Steven M ^e   Holman, Rury R ^c   Chang, Futien ^f   Giles, Thomas D ^g   Maggioni, Aldo P ^h   Rutten, Guy E H M ⁱ   Standl, Eberhard ^j   Thomas, Laine ^b   Tognoni, Gianni ^a   Califf, Robert M ^k   McMurray, John J V ^l  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d SANTA CHIARA HOSPITAL   (Italy)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ANMCO RESEARCH CENTER   (Italy)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; NATEGLINIDE; VALSARTAN;

ADULT; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; DIET RESTRICTION; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 84886858805     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.08.012     Document Type: Article

References (24)

1. Y. Miyasaka, M.E. Barnes, and B.J. Gersh Secular trends in incidence of atrial fibrillation in Olmsted Country, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125
2. H. Stefansdottir, T. Aspelund, and V. Gudnason Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections Europace 13 2011 1110 1117
3. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery A.J. Camm, and P. Kirchhof Guidelines for management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
4. D. Conen, C.U. Chae, and R.J. Glynn Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation JAMA 305 2011 2080 2087
5. M. Allessie, J. Ausma, and U. Schotten Electrical, contractile and structural remodeling during atrial fibrillation Cardiovasc Res 54 2002 230 246
6. M.K. Stiles, B. John, and C.X. Wong Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: characterizing the "second factor" J Am Coll Cardiol 53 2009 1182 1191
7. E.J. Benjamin, D. Levy, and S.M. Vaziri Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 271 1994 840 844
8. R.B. Schnabel, L.M. Sullivan, and D. Levy Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study Lancet 373 2009 739 745
9. A.D. Krahn, J. Manfreda, and R.B. Tate The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-up Study Am J Med 98 1995 476 484
10. L. Frost, L.J. Hune, and P. Vestergard Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, And Heath Study Am J Med 118 2005 489 495
11. M.R. Movahed, M. Hashemzadeh, and M.M. Jamal Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease Int J Cardiol 105 2005 315 318
12. J.G. Smith, P.G. Platonov, and B. Hedblad Atrial fibrillation in the Malmö Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity Eur J Epidemiol 25 2010 95 102
13. R.R. Huxley, K.B. Filion, and S. Konety Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation Am J Cardiol 108 2011 56 62
14. T. Schoen, A.D. Pradhan, and C.M. Albert Type 2 diabetes mellitus and risk of incident atrial fibrillation in women J Am Coll Cardiol 60 2012 1421 1428
15. H. Watanabe, N. Tanabe, and T. Watanabe Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study Circulation 117 2008 1255 1260
16. D. Preiss, L.E. Thomas, and J.L. Sun Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial BMJ Open 2 6 2012
17. The NAVIGATOR Study Group Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
18. The NAVIGATOR Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1463 1476
19. P.M. Okin, K. Wachtell, and R.B. Devereux Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension JAMA 296 2006 1242 1248
20. R.R. Huxley, F.L. Lopez, and A.R. Folsom Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study Circulation 123 2011 1501 1508
21. M. Disertori, F. Lombardi, and S. Barlera Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial Am Heart J 159 2010 857 863
22. A.P. Maggioni, R. Latini, and P.E. Carson Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) Am Heart J 149 2005 548 557
23. GISSI-AF Investigators Valsartan for prevention of recurrent atrial fibrillation N Engl J Med 360 2009 1606 1617
24. B. Dahlöf, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003